Abstract 14227: Fatty Acid-Binding Protein-3 and Renal Function Decline in Patients With Chronic Coronary Syndrome

• Published in: Circulation (New York, N.Y.) Vol. 148; no. Suppl_1; p. A14227
• Main Authors: Huang, Chin-Chou, Yeh, Jiunn-Tyng
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 07.11.2023
• Subjects: Renal Failure; Kidney Disease; Renal function; Coronary artery disease
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.148.suppl_1.14227

Introduction: Renal dysfunction is common in patients with coronary artery disease. To delay the development of end-stage kidney disease and improve chronic kidney disease prognosis, early detection and management of chronic kidney disease are crucial, especially for high-risk populations. Hypothesis: We hypothesized that the fatty acid-binding protein-3 (FABP-3) is a novel biomarker associated with renal dysfunction. Methods: This is a multicentre prospective cohort study. Patients with chronic coronary syndrome were classified into three groups based on the initial serum FABP-3 levels. The Modification of Diet in Renal Disease (MDRD) equation was used to estimate the patient's renal function. Renal events were defined as >25% and >50% decline in estimated glomerular filtration rate (eGFR). Multivariable Cox regression was employed to delineate the correlation between FABP-3 and renal dysfunction. Results: A total of 1606 subjects were included. During a mean follow-up of 35.9 months, there were 274 patients with eGFR >25% reduction and 60 patients with >50% reduction. The Kaplan-Meier survival curves showed that increased levels of FABP-3 were significantly correlated with eGFR >25% reduction (P < 0.001) and >50% reduction (P < 0.001). Multivariate Cox regression model revealed that subjects with higher FABP-3 exhibited a greater risk of eGFR >25% reduction (Group 2: HR = 1.742, 95% CI = 1.222-2.483; Group 3: HR = 2.643, 95% CI = 1.847-3.784) and >50% reduction (Group 2: HR = 3.818, 95% CI = 1.261-11.564; Group 3: HR = 9.769, 95% CI = 3.291-29.002). Conclusions: Serum FABP-3 may serve as a novel biomarker to predict eGFR decline in patients with chronic coronary syndrome. 1